REG - Oxford Cannabinoid - Total Voting Rights

Oxford Cannabinoid Technologies HoldingsAnnouncement

29/02/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240229:nRSc8187Ea&default-theme=true

RNS Number : 8187E  Oxford Cannabinoid Tech.Holdings  29 February 2024

 

Oxford Cannabinoid Technologies Holdings plc

("OCT" or the "Company")

 

Total Voting Rights

 

In accordance with the Financial Conduct Authority's (FCA) Disclosure Guidance
and Transparency Rule 5.6.1, Oxford Cannabinoid Technologies Holdings plc
(LSE:OCTP) confirms that as of 29 February 2024, its issued share capital
consists of 1,088,415,644 ordinary shares of 0.1 pence each, (Ordinary
Shares), each with one voting right. The Company does not hold any shares in
treasury. Therefore, the total number of voting rights on 29 February 2024 is,
1,088,415,644.

 

This figure should be used by shareholders as the denominator for calculations
by which they can determine if they are required to notify their interest in,
or a change to their interest in, the Company under the FCA's Disclosure
Guidance and Transparency Rules.

 

The Directors of the Company take responsibility for this announcement.

 

Enquiries:

 

 Oxford Cannabinoid Technologies Holdings plc  +44 (0)20 3034 2820
 Clarissa Sowemimo-Coker (CEO)                 clarissa@oxcantech.com

 Cairn Financial Advisers LLP
 Emily Staples                                 +44 (0)20 7213 0897
 Jo Turner                                     +44 (0) 20 7213 0885

 Axis Capital Markets Limited
 Richard Hutchison                             +44 (0)20 3026 0320

 Acuitas Communications                        020 3745 0293 / 07799 767676
 Simon Nayyar                                  simon.nayyar@acuitascomms.com
 Arthur Dingemans                              arthur.dingemans@acuitascomms.com

 

About Oxford Cannabinoid Technologies Holdings Plc:

OCT is the holding company of Oxford Cannabinoid Technologies Ltd and OCT
Victoria Pty Ltd (together the "Group"), a pharmaceutical Group developing
prescription cannabinoid medicines initially targeting the US$ multi-billion
global pain market.

 

OCT currently has a portfolio of four drug development programmes. Its lead
compound, OCT461201, will initially target neuropathic and visceral pain
(including irritable bowel syndrome ("IBS") and chemotherapy induced
peripheral neuropathy ("CIPN"). The global market for CIPN alone is currently
forecast to reach US$1.17bn by 2028.

 

OCT's drug development pipeline comprises both natural and synthetic
compounds, and includes compounds targeting trigeminal neuralgia, a severe
type of face pain, and cannabinoid derivatives targeting pain and potentially
other therapeutic areas. Having established an exclusive licence agreement
with Canopy Growth Corporation for their entire pharmaceutical cannabinoid
derivative library, OCT now has a portfolio of almost five hundred derivatives
and intellectual property rights including fourteen patent families and
associated research data.

 

OCT has a clearly defined path to commercialisation, revenues and growth. The
Group is developing drug candidates through clinical trials to gain regulatory
approval (FDA/MHRA/EMA) that will enable medical professionals to prescribe
them with confidence. OCT's portfolio aims to balance risk, value and time to
market, whilst ensuring market exclusivity around all its key activities.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRDZGZZZRLGDZM